Status:
COMPLETED
Harms of Hepatocellular Carcinoma Surveillance
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Parkland Health and Hospital System
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
21+ years
Brief Summary
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socio...
Detailed Description
Leveraging a multi-center randomized controlled trial assessing screening benefits in a socioeconomically and racially diverse population of patients with cirrhosis followed in 3 healthcare settings o...
Eligibility Criteria
Inclusion
- Inclusion and exclusion criteria of the parent randomized controlled trial are as follows:
- Adult patients (≥ 21 years old)
- Cirrhosis
- Outpatient visit in year prior to randomization
- English or Spanish speaking
Exclusion
- History of hepatocellular carcinoma
- History of liver transplantation
- Child Pugh C cirrhosis
- Significant comorbid conditions with life expectancy \< 1 year, (e.g., extrahepatic malignancy)
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
2871 Patients enrolled
Trial Details
Trial ID
NCT03756051
Start Date
April 1 2018
End Date
June 30 2022
Last Update
December 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390